T1	Participants 588 670	335 patients were randomized into treatment with the oral administration of XS0601
T2	Participants 1077 1131	308 patients (91.9%) completed the study and 145 cases
T3	Participants 1262 1275	placebo group
T4	Participants 1686 1698	XS0601 group
T5	Participants 1742 1755	placebo group
T6	Participants 1866 1878	XS0601 group
T7	Participants 1996 2013	post-PCI patients
